Skip to main content

Welcome New Corporate Partners (June 2024)

Welcome Fingerpaint and Zymeworks

The HBA is proud to welcome new corporate partners to help lead the charge for furthering the advancement and impact of women in the business of healthcare. It’s these bold companies who are seen as an employer of choice for women and top talent.

As we welcome these new companies to our United Force for Change community, let’s learn a little more about them:

Fingerpaint
CEO: Ed Mitzen

Reset your expectations of a marketing agency. Independent by design, with integrated talent across Saratoga Springs, New York; Conshohocken, Pennsylvania; Phoenix, Arizona; and Cedar Knolls, New Jersey, Fingerpaint is committed to creating and executing meaningful brand experiences that are never paint by number. Fingerpaint was named 2019 Agency of the Year by Med Ad News. It was a 2017 finalist for Agency of the Year by Med Ad News, MM&M, and PM360 and won PR & Marketing Agency of the Year in 2017 from the Business Intelligence Group. Additionally, it won the 2018 Heart Award from Med Ad News for its commitment to philanthropy and social causes and has been on Inc. Magazine's list of the 5,000 Fastest-Growing Companies for the past six years. Founder Ed Mitzen was honored as 2016's Industry Person of the Year by Med Ad News and as a 2017 Top Boss by Digiday.

Zymeworks
CEO: Kenneth Galbraith

Zymeworks is a clinical-stage biopharmaceutical company dedicated to the development of next-generation multifunctional biotherapeutics. Zymeworks’ lead clinical candidate, zanidatamab (ZW25), is a novel Azymetric™ bispecific antibody that has been granted Breakthrough Therapy designation by the FDA and targets HER2-expressing cancers. Zymeworks’ second clinical candidate, ZW49, is a novel bispecific HER2-targeting antibody-drug conjugate currently in Phase 1 clinical development. In addition, Zymeworks is advancing a deep preclinical pipeline in oncology and other therapeutic areas, and the Company’s therapeutic platforms are being leveraged through strategic partnerships with nine biopharmaceutical companies.

To learn more about Corporate Partner Benefits please click here

.